A Phase 1, Open Label Study to Evaluate the Pharmacokinetics and Safety of EXPAREL® Following Subcutaneous Administration in Healthy Chinese Subjects

Nuance Pharma (shanghai) Co., Ltd1 site in 1 country20 target enrollmentNovember 7, 2019

ConditionsHealthy Subjects

InterventionsBupivacaine liposome injectable suspension

DrugsBupivacaine liposome injectable suspension

Overview

Phase: Phase 1
Intervention: Bupivacaine liposome injectable suspension
Conditions: Healthy Subjects
Sponsor: Nuance Pharma (shanghai) Co., Ltd
Enrollment: 20
Locations: 1
Primary Endpoint: plasma concentration
Status: Completed
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This is a single-center, open-label, single-dose study to evaluate the safety, pharmacokinetics in healthy subjects

Detailed Description

This is a phase I, open-label, single-dose in healthy subjects conducted at single center.The objectives are to evaluate the metabolic and safety profile of EXPAREL®. Each volunteer will receive one dose of the investigational drug via subcutaneous injection at multiple points during the study period. Study duration is around 54 days, including screening, confinement, ambulatory visit and a phone follow up.

Registry

clinicaltrials.gov

Start Date

November 7, 2019

End Date

December 26, 2019

Last Updated

6 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Nuance Pharma (shanghai) Co., Ltd

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Chinese male or female subjects, and his/her biological parents and grandparents are of Chinese ethnicity.
•Aged ≥18 and ≤55 years of age at screening, inclusive.
•Willing and able to give written informed consent and comply with the study visit schedule, study procedures and restrictions.
•Generally, in good health with no clinically significant abnormalities as determined by medical history, physical examination, 12-lead ECG and clinical laboratory tests.
•Have a body mass index (BMI) between 19.0 and 24.0 kg/m2, inclusive, and a body weight ≥50 kg at screening visit and baseline visit (Day -1).

Exclusion Criteria

•Female subjects who are pregnant (positive pregnancy result at screening and on Day -1), or lactating.
•Female subjects of child bearing potential and sexually active don't agree to use medically acceptable contraceptive (e.g. insertable, injectable, transdermal, hormonal contraceptive) from the date of consent given until 30 days after administration of study drug. Menopausal woman don't have her menopausal status confirmed by follicle-stimulating hormone test at screening.
•Male subjects who are sexually active don't agree to use condom plus spermicide since the dosing day till 90 days after administration of study drug.
•Male subjects don't agree not to donate sperm since the dosing day till 90 days after administration of study drug.
•Presence of any concomitant clinically significant diseases, that would interfere with the study based on the investigator's discretion.
•History of hypersensitivity or idiopathic reaction to amide-type local anesthetics.
•Has a positive urine drug screen result for drugs of abuse or a positive blood alcohol test at the Screening Visit or baseline visit (Day-1).
•Has an abnormal (clinically significant) ECG at the screening visit. Entry of any subject with an abnormal (but not clinically significant) ECG must be approved and documented by signature of the Investigator or medically qualified subinvestigator.
•Has a supine BP outside the ranges of 90 to 140 mmHg for systolic BP and 50 to 90 mmHg, inclusive, for diastolic BP, or resting pulse rate outside the range of 40 to 100 beats per minute. If any of the values are out of range, the assessment may be repeated twice for eligibility determination at the screening visit or baseline visit (Day-1).
•Positive HIV test result at screening.